Enhanced transforming growth factor-b1 (TGF-b1) expression in renal cells promotes fibrosis and hypertrophy during the progression of diabetic nephropathy. The TGF-b1 promoter is positively controlled by the E-box regulators, upstream stimulatory factors (USFs), in response to diabetic (high glucose) conditions; however, it is not clear whether TGF-b1 is autoregulated by itself. As changes in microRNAs (miRNAs) have been implicated in kidney disease, we tested their involvement in this process. TGF-b1 levels were found to be upregulated by , and TGF-b1 in mouse mesangial cells, and in mouse kidney cortex. Thus, miRNA-regulated circuits may amplify TGF-b1 signaling, accelerating chronic fibrotic diseases such as diabetic nephropathy.
Diabetes mellitus is associated with several debilitating complications including kidney disease or diabetic nephropathy (DN), a main cause for patients requiring painful and costly dialysis. Accumulation of extracellular matrix proteins such as collagen in the kidney mesangium and tubulointerstitium is one of the major hallmarks of DN and contributes to renal failure. 1, 2 Transforming growth factor-b1 (TGF-b1) levels and signaling are enhanced in renal cells during the progression of DN. TGF-b1 plays a key role in mesangial cell fibrosis under diabetic conditions by inducing the expression of extracellular matrix proteins such as collagen.
2-8 TGF-b1 is upregulated by high glucose (HG) in mesangial cells (MCs) via the binding of upstream stimulatory factors (USFs; positive regulators) at the glucose-response element (CACGTG, also a typical E-box motif) in its promoter. [9] [10] [11] On the other hand, TGF-b1 induces the expression of the collagen type I a2 (Col1a2) gene by inhibiting the expression of the E-box repressors, Zeb1/2, while increasing Tfe3 (transcription factor binding to IGHM enhancer 3), another positive regulator of E-boxes. 4, 12 Under basal conditions, Zeb1/2 repressors negatively regulate Col1a2 expression by binding to E-box elements in the far upstream region of the Col1a2 promoter. 4, 12 ZEB1/2 are now widely recognized as general E-box repressors that bind to E-box elements in the promoters of genes such as E-cadherin and collagens, resulting in their repression. [13] [14] [15] [16] [17] MicroRNAs (miRNAs) are short (B22 nucleotides) noncoding RNAs that are important regulators of gene expression. 18, 19 miRNAs induce post-transcriptional gene repression by blocking protein translation via binding to the 3 0 untranslated region (UTR) of their target genes, or by inducing mRNA degradation, and therefore have the potential to play central roles in gene expression under physiological and pathological conditions. Their widespread and distinct expression patterns under normal and disease states make miRNAs attractive molecular therapeutic targets for human diseases, especially because of the recent advances in the development of chemically modified inhibitors of miRNAs like antagomirs 20 and locked nucleic acid (LNA) antimiRs. 21, 22 miRNAs are also involved in progressive kidney diseases. 23 miR-192 is upregulated by TGF-b1 in mouse MCs (MMCs) 4 and by HG in human MCs, 24 and in glomeruli of diabetic mice, demonstrating that diabetic conditions induce miR-192. Zeb2 is targeted and negatively regulated by miR-192 in response to TGF-b1 in MMCs and this leads to increased collagen expression due to relief of repression. 4 TGF-b1 and miR-192 levels are increased along with enhanced fibrosis in the kidneys of diabetic FXR knockout mice. 25 miR-192 is also upregulated in the kidneys of other models of renal fibrosis (unilateral ureteral obstruction in mice and a rat model of remnant kidney disease) and in tubular epithelial cells treated with TGF-b1 in a Smad3-dependent manner. 26 On the other hand, one study showed that TGF-b1 treatment decreased miR-192 expression in a tubular epithelial cell line. 27 Targeted deletion of Dicer, a key enzyme involved in miRNA biogenesis, from proximal tubules could protect against renal ischemia-reperfusion injury. 28 As miR-192 levels were decreased in these tubular-specific Dicer knockout mice, these data suggest that miR-192 inhibitors might be beneficial in models of kidney injury and disease. miR-192 and miR-200 family members regulate Zeb1/2 in epithelial-tomesenchymal transition (EMT) in cancer cells and other established cell lines as Zeb1/2 are also repressors of E-cadherin. 27, [29] [30] [31] [32] [33] [34] [35] miR-200 family members are also autoregulated by Zeb1/2 through E-boxes in their promoters. 31, 36 Although TGF-b1 expression is induced by HG in MCs via the binding of USFs to E-boxes in the TGF-b1 promoter, [9] [10] [11] it is not clear if the TGF-b1 promoter is autoregulated by TGF-b1 itself or miRNAs. Here, we report that TGF-b1 is upregulated by TGF-b1 through miR-192 and miR-200b/c that target Zeb1/2. Furthermore, we observed that miR-200b/ c are also directly induced by miR-192, implicating miR-192 as a key upstream regulatory renal miRNA. These miRNAdependent positive feedback amplifying circuits may play major roles in accelerating TGF-b1 expression and signaling under diabetic conditions as proposed previously.
22,37

RESULTS
Autoregulation of TGF-b1 is mediated by miR-192 in MMCs
TGF-b1 mRNA levels were significantly increased in MMCs treated with TGF-b1 for 24 h in a dose-dependent manner (5-10 ng/ml; Figure 1a ). Time course showed no significant increase of TGF-b1 mRNA levels at earlier time points (1 or 6 h; Figure 1b ). To test whether the TGF-b1 promoter is also activated by TGF-b1, MMCs were transfected with pA835luc (luciferase reporter plasmid driven by the mouse TGF-b1 promoter containing glucose response element, (a) Dose-response curve of TGF-b1 mRNA levels (assessed by quantitative real-time PCR) in MMCs treated with exogenous recombinant TGF-b1 for 24 h (mean and s.e., n ¼ 4). Significant increase was detected at 5-10 ng/ml of TGF-b1. (b) Time course study of TGF-b1 mRNA levels in MMCs treated with 10 ng/ml of TGF-b1 (mean and s.e., n ¼ 4). Significant increase was detected only at 24 h. (c) Mouse TGF-b1 promoter (including upstream glucose response element, CACGTG, also known as E-box) Luc reporter (pA835luc) activity was significantly increased by TGF-b1(10 ng/ml for 24 h) (mean and s.e., n ¼ 4). SD, serum depletion. (d) miR-192 mimic oligonucleotides (oligos) increased TGF-b1 promoter Luc reporter (pA835luc) activity, whereas miR-192 inhibitor oligos inhibited the TGF-b1-induced reporter activity (mean and s.e., n ¼ 4). NC, negative control oligo. ***Po0.001, **Po0.01, and *Po0.05, respectively.
CACGTG, also known as E-box).
9,38 A significant increase (approximately twofold) in luciferase activity was observed in MMCs treated with TGF-b1 (Figure 1c ). These results demonstrate that TGF-b1 induces its own expression and promoter activity (autoregulation) in MMCs.
Next, we tested whether miR-192 can regulate the TGF-b1 promoter, because miR-192 increases gene expression through E-box enhancer elements by downregulating the Ebox repressors Zeb1/2, 4,22 and the TGF-b1 promoter is also regulated by an E-box in its promoter. [9] [10] [11] Transfection of MMCs with miR-192 mimic significantly increased reporter activity of pA835luc in MMCs compared with negative control (NC; Figure 1d ). Conversely, miR-192 inhibitor significantly decreased reporter activity under basal as well as TGF-b1-treated conditions. These results suggest that inhibition of Zeb1/2 by miR-192 may enhance TGF-b1 promoter activity in response to TGF-b1. As miR-200 family members target both Zeb1 and Zeb2, [29] [30] [31] [32] [33] [34] and are also self-regulated by Zeb1/2 through E-boxes in their promoters, 31, 36 As an increase of type IV collagens occurs in early stages of DN, 7, 8 
TGF-b1 increases USF1 and Tfe3 occupancies, but decreases Zeb1 occupancy on the TGF-b1 promoter E-box Next, we used chromatin immunoprecipitation (ChIP) assays to examine the occupancy of E-box regulators, USF1 and Tfe3 (positive) and Zeb1 (negative), on the TGF-b1 promoter in MMCs treated with TGF-b1 or HG (25 mmol/l). Occupancy was determined by amplification of TGF-b1 promoter E-box region (Figure 7a ) using quantitative realtime PCR of ChIP-enriched DNA. USF1 occupancy was significantly increased by HG treatment compared with normal glucose (5.5 mmol/l) or Mannitol (19.5 mmol/l) (Figure 7b ), as reported. 9 Interestingly, TGF-b1 treatment showed significant enrichment of USF1 as well as Tfe3, with reciprocal significant depletion of Zeb1 compared with untreated control (serum depletion; Figure 7c ). We also examined occupancies of these E-box regulators on the Col1a2 enhancer E-box region and observed that TGF-b1 increased Tfe3 and decreased Zeb1 enrichments at this Col1a2 enhancer as also noted in our previous studies. 4, 12 However, no significant change of USF1 occupancy on Col1a2 E-box region was detected (Figure 7d and e) . These results suggest that the downregulation of Zeb1 by miR-200b/ c induced by TGF-b1 can enhance both TGF-b1 and Col1a2. But the recruitment of USF1 to TGF-b1 promoter E-box region may be different from Col1a2 enhancer E-boxes. To evaluate the in vivo relevance, we tested the effects of miR-192 inhibition in mice using LNA-modified antisense miR-192 (LNA-antimiR-192). 22 Injection with LNA-antimiR-192 decreased the expression of miR-192, miR-141, miR200b, miR-200c, Col1a2, Col4a1, and TGF-b1 in the mouse renal cortical tissues in vivo (Figure 8b ).
DISCUSSION
In this study, we observed for the first time that TGF-b1 can be auto-upregulated in MMCs by the activation of a miRNA cascade including miR-192 and key miR-200 family members. It is likely that, initially, diabetic conditions (HG) induce TGF-b1 through various mechanisms including binding of USFs (E-box activators) to its promoter. promoter has Smad and p53 binding sequences and is upregulated by Smad3 or p53. 26, 40 Then, miR-192 can target and downregulate Zeb1/2 (E-box repressors) 4, 27, 35, 41 and thereby enhance the expression of TGF-b1 through the recruitment of USF1 and Tfe3 but dissociation of Zeb1 from the E-box region in the TGF-b1 promoter to create an amplifying circuit (Figure 9 ). Interestingly, we found that key miR-200 family members were also upregulated by TGF-b1 in MMCs and in the glomeruli of diabetic mice. In addition, miR-192 also increased miR-200b/c (Figure 3) probably through E-boxes in their promoters. miR-200b also increased Col1a2 expression and promoter activity by collaborating with miR-192 ( Figure 6 ). Simultaneous transfection of miR-192 (inhibitor of Zeb2) and miR200b (inhibitor of Zeb1) was necessary for significant induction of Col1a2 or its promoter activity ( Figure 6 ). These results are consistent with previous data showing that Zeb2 inhibition by miR-192 alone was not sufficient but also needed Zeb1 inhibition (by short hairpin RNAs) to elicit a significant increase in Col1a2 expression in MCs. 4 On the other hand, single transfection of an inhibitor of either miR-192 or miR-200b was sufficient to inhibit Col1a2 expression and its promoter activity ( Figure 6 ). Thus, inhibition of both Zeb1 and Zeb2 is necessary for significant induction of Col1a2, whereas the presence of just one of these repressors (Zeb1 or Zeb2) is sufficient to suppress Col1a2. However, unlike Col1a2, miR-200b/c, Col4a1, and TGF-b1 were upregulated by either miR-192 or miR-200b alone ( Figures  3 and 6 ). As Col1a2 upstream E-box region is regulated by multiple factors like Tfe3, Tsc-22, and Ybx1 12 besides Zeb1/2, induction of Col1a2 might involve additional or more complex mechanisms compared with TGF-b1 Col4a1 or miR-200 family promoters.
ChIP experiments showed significant decrease of Zeb1 occupancy on E-box regions of TGF-b1 promoter and Col1a2 enhancer in MMCs treated with TGF-b1 (Figure 7) . These results further support the notion that suppression of E-box repressor Zeb1 by miR-200b/c induced by TGF-b enhances the expression of TGF-b1 and Col1a2. Although E-box activator Tfe3 occupancy was increased by TGF-b1 at E-box regions of both TGF-b1 and Col1a2 genes, USF1 occupancy was increased only at E-box region of TGF-b1 gene. These results demonstrate similarities in the regulation of these two genes with respect to decrease in Zeb1, but differences in the recruitment of positive factors. As we noted at least 12 potential E-boxes in the Col4a1 gene promoter, Col4a1 may be regulated by TGF-b1, miR-192, or miR-200b through these E-boxes similar to the regulation of TGF-b1, miR-200b, and Col1a2, although more studies are required to clarify this.
miR-200 family members also regulate Zeb1 and Zeb2 in EMT in cancer [29] [30] [31] [32] [33] [34] and were decreased during EMT of the canine kidney cell line (MDCK) treated with TGF-b1 for long time periods (2-3 weeks). 29 As type I collagen induces EMT, 42, 43 it is possible that there is a biphasic regulation in which miR-192 and 200 family are upregulated by TGF-b1 at early time points (6-24 h) that decreases Zeb1 and Zeb2 to induce type I collagen in MMCs. This increase in collagen may subsequently induce EMT (maybe by decreasing these miRNAs) at later time points. In the NRK52E epithelial cell line, Chung et al. 26 reported that miR-192 levels were increased by 2 ng/ml TGF-b1 at 1-24 h, whereas Wang et al. 35 reported that miR-192 levels were decreased by 10 ng/ml TGF-b1 at 3 days with no data at earlier time points. Although the dose of TGF-b1 might dictate its response, it is possible that initially TGF-b1 increases miR-192 and miR-200 family to promote type I collagen expression (up to 24 h), whereas miR-192 levels may be reduced at later time periods (3 days to weeks). Furthermore, there is no EMT in mesangial cells, and hence, it is highly likely that the response of miRNAs to TGF-b may be cell-type specific and context dependent. On the other hand, fibrosis and accumulation of extracellular matrix proteins in MCs and tubular cells are well-established features of DN in both human and mice.
1,2 Thus, the upregulation of collagen expression by TGF-b1 via increases in miR-192 and miR200b and concomitant decrease in Zeb1/2 in MCs may be a key feature of DN and possibly more relevant during the early stages of diabetic kidney injury. Interestingly, increased levels of miR-192 and miR-200 family were observed in human kidneys from patients with hypertensive nephrosclerosis, IgA nephropathy, and lupus nephritis, [44] [45] [46] and in some animal models of kidney injury, 25, 26, 28 further supporting the miRNA-mediated mechanism of TGF-b1 auto-upregulation and enhanced renal fibrosis. On the other hand, it was also reported that miR-192 expression decreased with increased severity of DN and fibrosis; however, normal levels of miR-192 in healthy kidneys were not provided for comparison. 27 Clearly, more work is needed to further evaluate these aspects in renal cells.
Notably, miR-192 is regulated by Smad3 and p53. 26, 40 Numerous mutations in p53 and Smad genes have been found in cancer cells and immortalized cell lines [47] [48] [49] that may affect the miR-192 response to TGF-b1 in these cells. In other words, p53 and Smad genes may also be decision makers of TGF-b1 response. In fact, mutant p53 changes the response to TGF-b1 via Smad interaction. 50 Kidney injury and fibrosis were inhibited in p53 or Smad3 knockout mice. 26, 51 In this study, we used primary mouse MCs and glomeruli that have normal intact p53 and Smad genes. Therefore, the response of miR-192 and miR-200 family to TGF-b1 in primary MMCs may be different from those reported in cancer or immortalized kidney cell lines, and might explain some of the discrepancies in TGF-b1 responses. They also indicate the importance of using primary cells (at early passage) for studying models of renal fibrosis or injury and especially the mediatory role of miRNAs.
miR-200 family was also reported to control phosphatidylinositol-3-kinase signaling by targeting Fog2, an inhibitor of phosphatidylinositol-3-kinase. 52 As phosphatidylinositol-3-kinase/Akt activation in diabetic kidney cells induces hypertrophy and fibrosis, 12, 22, 53, 54 upregulation of miR-200 family members may also activate Akt through inhibition of Fog2 to promote mesangial hypertrophy. As miR-192 also activates Akt kinase and fibrosis by inducing miR-216a and miR-217 that target Pten, 22 this cascade of miRNAs (miR-200 family, miR-216a, and miR-217) initiated by miR-192 may enhance Akt activation, hypertrophy, and fibrosis in MCs.
In summary, these novel miR-mediated circuits demonstrated in this study can lead to the auto-upregulation of TGF-b1 and amplification of TGF-b1 signaling, and thereby accelerate chronic fibrotic kidney diseases including DN ( Figure 9 ). The ability of the miR-192 inhibitor to repress the expression of miR-200 family members, TGF-b1, Col4a1, and Col1a2, both in vitro (MMCs treated with TGF-b1) and in vivo (mouse kidney cortex), suggests that miR-192 could be a novel target for the prevention or treatment of fibrotic disorders like DN as well as other diseases where TGF-b signaling is hyperactive.
MATERIALS AND METHODS Mice
All animal studies were conducted according to a protocol approved by the institutional animal care and use committee. Induction of diabetes by streptozotocin injections in C57BL/6 mice was carried out as described. 4 Mice were used 7-8 weeks after the onset of diabetes. Type 2 diabetes db/db mice and genetic control db/ þ mice (10-12 weeks old) were obtained from Jackson Laboratories (Bar Harbor, ME). Glomeruli were sieved from renal cortical tissue as described. 4, 53 Cell culture Primary MMCs were isolated and cultured as described. 4 Recombinant human TGFb1 was from R&D Systems (Minneapolis, MN).
Real-time quantitative PCR
Real-time quantitative PCR was performed using SYBR Green PCR Master Mix and 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA), as reported. 4, 12, 22 PCR primer sequences were: mouse TGF-b1, 5 0 -GGACTCTCCACCTGCAAGAC-3 0 and 5 0 -GACT GGCGAGCCTTAGTTTG-3 0 ; mouse Col4a1, 5 0 -GCCTTCCGGGCT CCTCAG-3 0 and 5 0 -TTATCACCAGTGGGTCCG-3 0 . miRNA expression levels were also confirmed by miScript System (Qiagen, Valencia, CA).
Western blot analyses These were performed as described. 4 Antibodies against ZEB1 (Santa Cruz Biotechnology, Santa Cruz, CA) and b-actin (Cell Signaling, Beverly, MA) were used in a 1:1000 dilution.
Plasmids and 3
0 UTR reporters pA835luc was a generous gift from Dr Kumar Sharma (University of California, San Diego). 9, 38 Mouse Col1a2 promoter luciferase plasmid (E-box-Col1a2P-luc) was described previously. 12 3 0 UTR of mouse Zeb1 was amplified using primers Zeb1-3 0 UTR-F, 5 0 -CCAACTCGAGT TCTTCTAAAAGGAAATTCTACTTGG-3 0 and Zeb1-3 0 UTR-R, 5 0 -GA GAGCGGCCGCGGGAATTCTGTAGTGCAGAAGTTCTC-3 0 . The PCR fragment was digested with XhoI and NotI and cloned into psiCheck2 (Promega, Sun Luis Obispo, CA). Potential miR200b/c site mutants were made by site-directed mutagenesis as described 22 
Luciferase assays
MMCs were transfected with plasmids and/or miRNA mimics or inhibitors using Nucleofector (Lonza, Walkersville, MD). Basic Nucleofector Kit (Lonza) was used. After 48 h, luciferase activities were measured as described. 4, 22 miRNA oligonucleotides Oligonucleotides representing the miRNA mimics, the NC mimics, miRNA inhibitors, and NC inhibitors were obtained from Dharmacon (Lafayette, CO). LNA-modified anti-miR-192 was from Exiqon (Vedbaek, Denmark). 22 
ChIP assays
ChIP assays were performed as reported. 4, 9, 12, 22 Briefly, MMCs were treated with 10 ng/ml TGF-b1 or HG (25 mmol/l) condition for 24 h and then formaldehyde fixed. The crosslinked chromatin was sheared and immunoprecipitated using antibodies against USF1 (Santa Cruz Biotechnology), Tfe3 (BD Bioscience, San Diego, CA), or Zeb1. ChIP-enriched DNA was purified and used as template for real time quantitativeqPCRs using primers spanning Col1a2 or TGFb1 E-box regions as described. 4, 9 LNA-antimiR injections in mice LNA anti-miR-192 was subcutaneously injected (2.5 mg/kg) into C57BL/6 mice and renal cortical tissues harvested 6 h later as previously described. 22 
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